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Abstract 
Background: Bullous pemphigoid (BP) is an autoimmune bullous disease of the skin 
characterized by subepidermal blister formation due to tissue-bound and circulating 
autoantibodies to the hemidesmosomal antigens BP180 and BP230. Although eosinophils 
and their toxic mediators are found abundantly in BP lesions, their role in blister formation 
has remained unclear.  
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Objective: To investigate the role of eosinophils in the pathogenesis of BP with a specific 
focus on blister formation and to define conditions inducing dermal-epidermal separation 
(DES).  
Methods: In an ex vivo human model of BP, normal human skin cryosections were 
incubated with purified human peripheral blood eosinophils with or without activation in the 
presence or absence of BP autoantibodies, brefeldin A, diphenyleneiodonium (DPI), DNase, 
or blocking F(ab’)2 fragments to CD16, CD18, CD32 and CD64. DES was assessed by light 
microscopy studies and quantified using Fiji software.  
Results: Following activation with IL-5 and in the presence of BP autoantibodies, 
eosinophils induced separation along the dermal-epidermal junction of ex vivo skin. DES 
was significantly reduced by blocking any of the following: Fc receptor binding (p=0.048), 
eosinophil adhesion (p=0.046), reactive oxygen species (ROS) production (p=0.002), 
degranulation (p<0.0001), or eosinophil extracellular trap (EET) formation (p=0.048).      
Conclusions: Our results provide evidence that IL-5-activated eosinophils directly contribute 
to BP blister formation in the presence of BP autoantibodies. DES by IL-5-activated 
eosinophils depends on adhesion and Fc receptor activation, requires elevated ROS 
production and degranulation, and involves EET formation. Thus, targeting eosinophils may 
be a promising therapeutic approach for BP.   
 
Introduction 
Eosinophils are found in a broad spectrum of infectious and non-infectious skin diseases, 
despite the fact that the skin is devoid of eosinophils under physiologic conditions (1). 
Eosinophils are under the control of eosinophil hematopoietins; in particular interleukin (IL)-5 
plays a critical role in regulating the production, differentiation, activation, trafficking and 
survival of eosinophils (2). The primary function of eosinophils has been considered to be 
related to host defence as they can function as potent destructive effector cells (3). By 
degranulation of toxic granule proteins or eosinophil extracellular trap (EET) formation, 
eosinophils are able to kill parasites and bacteria (3-5). On the other hand, eosinophils have 
also been accused of causing tissue damage (3, 7). According to their cytokine expression, 
functionally different subpopulations of eosinophils have been identified in skin diseases that 
might potentially regulate inflammatory responses and/or fibrosis (6).  
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Bullous pemphigoid (BP) is the most common autoimmune blistering disease of the 
skin which is associated with an autoimmune response to BP180 and BP230, two structural 
components of junctional adhesion complexes, the hemidesmosomes, and subsequent 
damage to the dermal-epidermal junction (DEJ) (8, 9). Autoreactive B and T cell responses 
against the hemidesmosomal antigens BP180 and BP230 have also been identified (10, 11). 
BP antigen-specific T cells were shown to produce both Th1 (interferon (IFN)-γ) and Th2 (IL-
5 and IL-13) cytokines (10).  
Moreover, eosinophil infiltration and dermal-epidermal separation (DES) are typical 
histological findings in BP. In agreement with the dominant presence of eosinophils, IL-5 as 
well as eotaxins were found abundantly in blister fluids (12, 13). On the other hand, despite 
the observations of metalloproteinase (MMP)-9 expression by eosinophils at sites of blister 
formation capable of cleaving the extracellular, collagenous domain of BP180 in vitro (14), 
deposition of granule proteins such as major basic protein (MBP), eosinophil-derived 
neurotoxin (EDN) and eosinophil cationic protein (ECP) in BP lesions (15, 16), as well as 
eosinophil extracellular DNA traps (EETs) directed toward the DEJ in BP specimens (17), a 
direct contribution of eosinophils to blister formation in BP has not yet been shown. In this 
study, applying an ex vivo skin model, we aimed at investigating the role of eosinophils in the 
pathogenesis of BP with a specific focus on blister formation.  
 
Methods 
Patient materials 
BP serum (BPS) samples (n=30) were obtained from untreated patients with clinically, 
histopathologically and serologically confirmed BP according to current criteria (18). Pooled 
BPS (n=30) containing both BP180 and BP230 as assessed by ELISA with a mean titre of 
106.13 U/ml and 39.88 U/ml, respectively, were used (19, 20). Normal human serum (NHS) 
samples were obtained from healthy donors without any history of immunosuppression 
and/or autoimmunity. Eosinophils were collected from the peripheral blood of patients with 
eosinophilic skin diseases attending the Department of Dermatology as well as from patients 
with hypereosinophilia diagnosed by the Institute of Pharmacology of the University of Bern 
(21, 22). Healthy human foreskin was obtained from routine circumcisions. The study has 
been approved by the Cantonal Ethics Committee (KEK) Bern. Written informed consent 
was obtained from all patients or their caregivers, prior to blood and tissue sampling.     
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Induction and evaluation of DES 
DES was analysed using an ex vivo model of DES as previously described (19) with minor 
modifications. Briefly, human foreskin was washed and embedded in an optimum cutting-
temperature compound (Tissue-Tek® O.C.T. ™ compound, Sakura Finetek Europe B.V, 
Alphen aan den Rijn, The Netherlands) and stored at -20°C. Six 6-µm thick cryosections 
were placed on adhesive microscope slides (Starfrost®, Medite Service AG, Dietikon, 
Switzerland). BPS and NHS were diluted 1:2 with PBS and applied to the skin sections for 2 
h at 37°C, followed by washing the slides with PBS. Eosinophils were resuspended in 
DMEM (DMEM plus GlutaMAX™, Gibco®, Life Technologies Europe B.V., Zug, 
Switzerland), including 10% foetal calf serum to avoid their immediate adherence to the 
slides, and subsequently added to the sections in the prepared chambers for an incubation 
of 4 h at 37°C. Tissue sections were then fixed with 3.7% formalin and stained with 
hematoxylin and eosin (H&E). DES was evaluated by light microscopy studies. The total 
lengths of DES and DEJ, respectively, were calculated using Fiji (23). DES was given as a 
percentage of separation at the DEJ. To assess tissue damage semi-quantitatively in 
indicated experiments, we scored the extent of skin damage and presence of DES. Each 
experiment was repeated at least three times to confirm reproducibility.   
 
Isolation of human eosinophils  
Peripheral blood eosinophils were isolated by density-gradient centrifugation using the Ficoll-
Hypaque technique (Pancoll, Bioswisstec AG, Schaffhausen, Switzerland). The upper phase 
containing peripheral blood mononuclear cells (PBMCs) was removed. The lower phase 
containing, eosinophils, neutrophils and erythrocytes was treated with a lysis solution (1.6 
mol/l NH4Cl, 100 mmol/l KHCO3, 1 mmol/l EDTA) to remove erythrocytes. Isolation of 
eosinophils was followed by a negative selection procedure with monoclonal antibodies 
bound in bispecific, Tetrameric Antibody Complexes (TAC), which were directed against 
CD2, CD3, CD14, CD16, CD19, CD20, CD36, CD56, CD123, glycophorin A and dextran 
(EasySepTM, STEMCELL Technologies, Grenoble, France). The negatively collected 
eosinophils were analysed by Hemacolor® Rapid staining (Merck Millipore, Darmstadt, 
Germany) and light microscopy. Fractions containing ≥ 95% mature eosinophils were 
employed for further experiments.  
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Activation of eosinophils 
In indicated experiments, eosinophils were stimulated with 25 ng/ml IL-5 (R&D Systems, 
Minneapolis, USA) or 100 ng/ml IFN-γ (R&D Systems) for 20 min at 37°C and/or with 10 nM 
complement factor 5a (C5a, Hycult Biotech, Uden, The Netherlands), 100 ng/ml 
lipopolysaccharides (LPS, Sigma-Aldrich, Buchs, Switzerland), 10 nM N-formyl-L-methionyl-
L-leucyl-L-phenylalanine (fMLF, Sigma-Aldrich) or 25 nM phorbol-myristate-acetat (PMA, 
Calbiochem, Merck&Cie, Darmstadt, Germany) for 15 min at 37°C before adding them to the 
cryosections. 
 
Blocking adhesion and Fcγ receptors (FcγR) 
To block adhesion, eosinophils were incubated with 20 µg/ml mouse F(ab’)2 fragments 
directed against human CD18 (Ancell Corporation, Bayport, USA) on ice for 45 min. To block 
FcγR-mediated effects, eosinophils were incubated with 10 µg/ml mouse F(ab’)2 fragments 
against CD16, CD32 and CD64 (all from Ancell Corporation, Bayport, USA) on ice for 45 
min. Isotype-matched mouse anti-human F(ab’)2 fragments (Jackson ImmunoResearch 
Europe Ltd. Suffolk, UK) served as controls.    
 
Pharmacological inhibition of ROS production, degranulation and EET formation 
To block reactive oxygen species (ROS) production, eosinophils were incubated with the 
NAPDH oxidase inhibitor diphenyleneiodonium chloride (DPI, Calbiochem, Merck Millipore, 
Darmstadt, Germany) at increasing concentrations of 1-75 µM for 30 min at 37°C. To block 
degranulation, eosinophils were incubated with 10 µg/ml brefeldin A (BFA, Sigma-Aldrich co, 
Buchs, Switzerland) which inhibits vesicular transport and granule emptying (24) for 30 min 
at 37°C. To degrade the DNA scaffold of EETs (5), 100 U/ml of deoxyribonuclease I (DNase 
I, Worthington Biochemical Corporation, Lakewood, USA) was used. All reagents were 
added to eosinophils prior to their application on skin sections.  
To quantify ROS production, 1 µM dihydro-rhodamine-123 (DHR, Sigma-Aldrich, 
Buchs, Switzerland) was added to activated eosinophils prior to their addition to human skin 
sections incubated with BPS, NHS or PBS in a black, glass-bottom 96-well plate (Greiner 
Bio-One GmbH, Frickenhausen, Germany) (25).  Fluorescence activity of the DHR 123 was 
measured at excitation 485 nm and the fluorescence emission at 538 nm, using a 
SpectraMaxM2 plate reader (Bucher Biotech, Basel, Switzerland) over a time period of 2 h. 
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Statistical analysis 
Data were analysed using Graph Pad Prism 5 software (La Jolla, CA, USA) and presented 
as means ± SEM. For comparison between treatments, unpaired 2-tailed t-tests or one-way 
ANOVA followed by Tukey’s multiple comparisons tests were applied. P values of ˂0.05 
were considered significant.  
 
Results 
IL-5 - activated eosinophils induce diffuse skin damage with focal DES 
In order to investigate the ability of eosinophils to induce DES, isolated peripheral blood 
eosinophils at concentrations of 10-40 x 106 cells/ml were added to human skin cryosections 
in the presence of either BPS or NHS. Under these circumstances, eosinophils failed to 
induce DES (Fig. 1A, 1B). In contrast, when the whole leukocyte fraction (30 x 106 cells/ml) 
or isolated neutrophils (30 x 106 cells/ml) were used, we observed an extensive DES of 
85.2% ± 3.4 and 47.2% ± 7.8, respectively, in the presence of BPS (Fig. 1A, 1C, 1D), but not 
NHS.    
To evaluate whether eosinophils stimulated with pro-inflammatory cytokines and 
mediators are able to induce DES in the ex vivo skin model, eosinophils were activated with 
IL-5 either alone or together with C5a or LPS before adding them to the cryosections. After a 
4-h incubation, IL-5-activated eosinophils caused a diffuse tissue damage with focal 
separation at the DEJ that was not further enhanced upon additional activation with C5a or 
LPS (Fig. 1E, 1F). As a positive control, we activated eosinophils with PMA, which is known 
to be a strong, but nonspecific stimulator of eosinophils (5, 26). PMA-stimulated eosinophils 
at concentrations of 20–30 x 106/ml induced massive diffuse skin damage leading to a 
complete loss of tissue structure (Fig. 1E). Moreover, we observed extensive extracellular 
eosinophil granule depositions in areas of tissue damage (Fig. 1G). Addition of PMA in the 
absence of eosinophils had no effect (Fig. 1H). Taken together, these results indicate that 
eosinophils activated with either IL-5 or PMA induced diffuse skin damage in an 
autoantibody-independent manner. 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Synergistic effect of interleukin-5 and BP autoantibodies on DES   
We next assessed whether BP autoantibodies have an impact on the DES-inducing effect of 
IL-5-activated eosinophils in our ex vivo skin model. Interestingly, in the presence of BP 
autoantibodies, we observed a line-up of IL-5–activated eosinophils at the DEJ after 3 h of 
incubation, where after 4 h, a marked DES was evident affecting 21.2% ± 2.3 of the DEJ 
(Fig. 2A-C). In contrast, IL-5–activated eosinophils in the presence or absence of NHS, 
induced significantly less DES of 9.3% ± 2.8 and 9.8% ± 1.8, respectively, suggesting that 
BP autoantibodies enhanced the activating effect of IL-5 on eosinophils to induce DES (Fig. 
2A, 2D). Additional stimulation of IL-5 and BPS - activated eosinophils with either IFN-, LPS 
or fMLF did not further increase the DES (data not shown).  
 
Eosinophil-induced DES requires FcγR and CD18  
A critical role for FcR in BP pathogenesis has been demonstrated in an animal model (26). 
In order to investigate the importance of FcγRs expressed by eosinophils for the binding of 
IgG autoantibodies present in BP serum, we used blocking F(ab’)2 fragments directed 
against CD16 (FcγRIII), CD32 (FcγRII) and CD64 (FcγRI) to block autoantibody binding on 
eosinophils. As a control, we used control F(ab’)2 fragments in these experiments. The 
blockage of FcγRs significantly reduced DES (Fig. 3A-C), suggesting that BP autoantibodies 
directly activate eosinophils and/or facilitate attraction of eosinophils to the DEJ in the 
presence of IL-5 through FcγRs.  
Since adhesion has been shown to play a crucial role for eosinophil activation (27), 
we tested whether blocking F(ab’)2 fragments directed against CD18, the common β chain 
shared by leukocyte integrins, inhibited eosinophil-mediated DES. Blockage of CD18 
significantly reduced DES, whereas isotype-matched control F(ab’)2 fragments did not (Fig. 
3D-F). Taken together, binding and adhesion of IL-5-activated eosinophils in the presence of 
BP autoantibodies appear to be mediated by FcγRs and CD18. 
 
ROS production, degranulation and EET formation are involved in DES induction by 
activated eosinophils 
We were next interested in potential molecular mechanisms by which IL-5 and BPS-
activated eosinophils induce DES. ROS production has been shown to be required for 
neutrophil-dependent autoantibody-induced tissue damage in an experimental model of 
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epidermolysis bullosa acquisita (28). Therefore, to evaluate the role of ROS in eosinophil-
induced DES, we tested the effect of DPI, a NADPH oxidase inhibitor, in our ex vivo skin 
model. Incubation of IL-5 and BPS - activated eosinophils with DPI decreased DES in a 
concentration-dependent manner (DES at 1 µM, 15.2% ± 3.9; 50 µM, 8.0% ± 4.0; 75 µM, 
2.8% ± 1.4; Fig. 4A, 4D, 4E). When the production of ROS by eosinophils co-incubated with 
skin sections was measured, we observed a rapid increase in ROS production in IL-5 - 
activated eosinophils after 5 min. ROS levels were then relatively constant for about 60 min 
and subsequently declined. In contrast, PMA-stimulated ROS production continued even 
after 60 min. DPI completely blocked IL-5-induced ROS production. It should be noted that 
we observed no increase in ROS production of IL-5-activated eosinophils in the presence 
BPS (Fig. 4H).   
Since eosinophil granule deposits have been observed in BP lesions (15, 16), we 
aimed to study the role of eosinophil degranulation on DES induction. Blocking degranulation 
of activated eosinophils by BFA (24, 29, 30) resulted in a significant inhibition of DES (Fig. 
4B, 4F) suggesting a direct contribution of eosinophil granule proteins to blister formation. 
In BP lesions, the presence of EETs consisting of DNA scaffold which granule 
proteins has been observed in close proximity to the DEJ (17). Furthermore, a destruction of 
the DNA scaffold by DNase was shown to abolish their functional properties in vitro (4, 5). To 
evaluate a possible role of EETs in DES, DNase was added to IL-5 and BPS – activated 
eosinophils prior to their application on the skin sections. DNase treatment significantly 
reduced DES induced by activated eosinophils (Fig. 4C, 4G).  
 
Discussion 
A direct contribution of eosinophils to blister formation in BP has long been suggested 
because of their characteristic presence in lesional skin, the demonstration of extracellular 
granule deposits near blisters (15, 16), EETs directed toward the DEJ (17), and BP antigen 
cleavage by the MMP-9 released by eosinophils (14). So far, animal models have 
demonstrated a possible pathogenic role of neutrophils, mast cells, and macrophages in BP 
(31-33). However, although eosinophils are the dominant cell type recruited to BP lesions, 
their contribution to blister formation has remained unclear.  
In this study, we provide evidence that activated eosinophils directly contribute to 
blister formation in BP patients. In order to induce DES, eosinophils required IL-5 activation. 
In the presence of BP autoantibodies, DES mediated by IL-5-activated eosinophils was 
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significantly increased. Under these conditions, we also observed an eosinophil lining at the 
DEJ, but no increased ROS production. Therefore, it is possible that eosinophils bind 
through their FcγRs to the autoantibodies bound to the DEJ that, however, seem to have 
less importance for eosinophil activation. DES might then be mediated by eosinophil granule 
proteins which damage the skin either alone or in the context of EET formation (4, 9). 
In agreement with a recent study, we observed that eosinophils activated solely with 
BP antibodies were not able to induce DES (34). Noteworthy, also similar to our study, IL-5-
activated eosinophils have previously been demonstrated to bind throughout the dermis and 
not specifically to the basement membrane (35). Our observations suggest that activated 
eosinophils may cause diffuse tissue damage with minimal DES, while in the presence of 
BPS, a line-up of eosinophils occurs at the DEJ, leading to an increased dermal-epidermal 
splitting.  
BP antibodies that are present in both serum and tissue of patients with BP (36) have 
been demonstrated to be essential for subepidermal blister formation in experimental mouse 
models (37). Antibodies against the 180-kD BP antigen were bound to the extracellular 
domain along the plasma membrane, while those against the 230-kD BP antigen were 
directed to the intracellular domain of the hemidesmosome (38). These antibodies were 
mainly of the IgG type and recognized the non-collagenous (NC) site of BP180 (39, 40). As 
BPS and purified IgG from the same sera were shown to have identical effects on DES in 
the ex vivo model and BPS-depleted of IgG reactive to NC16A, or F(ab’)2 fragments directed 
to NC16A, failed to induce DES (19), we abstained from a purification and detailed 
characterization of the BPS in the present study.  
The function of an anti-mBP180 IgG depends entirely on its Fc domain, whereas 
F(ab)2 of IgG failed to induce BP mediated by neutrophils in an animal model (26). Human 
eosinophils have been shown to constitutively express FcyRII (CD32) and small amounts of 
FcyRIII (CD16) that were enhanced upon IFN- stimulation (41, 42). Our results show that 
DES in the presence of BPS was highly dependent on functional FcRs on eosinophils. A 
role of other Fc receptors in eosinophil-mediated blister formation, e.g. Fc receptor in the 
subgroup of BP patients exhibiting IgE autoantibodies to BP180 or BP230 (43, 44) and 
responding to anti-IgE therapy (45), seemed unlikely since IgE autoantibodies in BP were 
shown to activate basophils and mast cells (46) rather than eosinophils that lack functionally 
active high-affinitiy IgE receptors (FcεRI) (47, 48). 
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In lesional BP skin, keratinocytes have been demonstrated to express the 
intercellular adhesion molecule (ICAM)-1 (49) and thus might attract and bind to eosinophils 
bearing CD11 and CD18 on their surface (50). In our ex vivo skin model, blocking CD18 with 
an anti-CD18 F(ab)2 fragment inhibited DES mediated by IL-5 and BPS-activated 
eosinophils, indicating that eosinophil adhesion may also play a role for blister formation in 
BP. 
Eosinophil degranulation with the release of toxic granule proteins subsequently 
leading to keratinocyte damage and DES has long been suggested as a key pathogenic 
event in BP (51, 52). Moreover, the deposition of granule proteins was shown to precede 
blister formation (15). Blocking eosinophil degranulation resulted in a significant decrease in 
DES formation, suggesting that eosinophil granule proteins play an important role for 
subepidermal blister formation in BP. Eosinophil granule proteins may also occur in 
association with extracellular DNA, forming so-called EETs (4, 5). Earlier work suggested 
that such EETs seem to target the DEJ in BP lesions (17). The observation that the 
destruction of the DNA scaffold by DNase significantly reduced DES induced by activated 
eosinophils point to the possibility that granule proteins present in EETs contribute to the 
subepidermal splitting in our ex vivo BP model.  
NADPH oxidase was shown to be required for autoantibody-dependent tissue 
damage by neutrophils enabling them to release superoxide in the extracellular space (28, 
53).  Compared with neutrophils, eosinophils may form even larger amounts of the NADPH 
oxidase complex upon activation (54). Moreover, increased ROS production has been 
demonstrated to be crucial for EET formation (4, 5). In this study, we show that 
pharmacological blocking of ROS production significantly reduced DES induction by 
activated eosinophils in a concentration-dependent manner. In this experimental setting, 
however, we were unable to distinguish whether the DPI effect was owing to an inhibition of 
EET formation, degranulation or extracellular ROS release, or a combination of these 
possibilities.  
Taken together, our study demonstrated that in the presence of BPS, IL-5-activated 
eosinophils had the capacity to split skin at the DEJ, thus directly contributing to 
subepidermal blister formation in BP. DES induced by activated eosinophils required 
eosinophil adhesion and functional FcRs, as well as ROS production and release of granule 
proteins which appear to mediate tissue damage either alone or in association with EETs. 
For future study of the role of eosinophils in BP in vivo, the following two approaches seem 
suitable: developing an animal model for eosinophilic BP or performing a specific targeting of 
eosinophils in BP patients (55). 
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Figure legends 
Figure 1 Activated eosinophils cause tissue damage. (A) Histology. Quantification of DES 
induced by leukocytes, neutrophils, and eosinophils in the presence and absence of BP 
autoantibodies. Values are means of the % separation ± SEM. ***, p<0.001; ****, p<0.0001; 
n=3. (B-D) Representative images (H&E) show the extent of DES (arrows) induced by 
eosinophils (panel B), leukocytes (panel C), and neutrophils (panel D) in the presence of 
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BPS. (E) Histology. Quantification of tissue damage and DES by activated eosinophils. 
Eosinophils were stimulated as indicated in the absence of BP autoantibodies. Values are 
means ± SEM. n=3. Each single experiment was performed with 6 cryosections. (F-H) 
Representative images (H&E) show the extent of tissue damage and DES (arrows) induced 
by eosinophils activated with IL-5 (panel F) or PMA (panel G) in the absence of BP 
autoantibodies. Asterisks point to extracellular eosinophil granules. PMA alone did not harm 
the skin (panel H). Magnification x20, except in panel B x40. 
 
Figure 2 Synergistic effect of IL-5 and BP autoantibodies on DES. (A) Histology. 
Quantification of DES induced by eosinophils in the presence and absence of IL-5 and BP 
autoantibodies. Values are means of % separation ± SEM. **, p<0.01; ****, p<0.0001; n=3. 
(B-D) Representative images (H&E) show the extent of DES (arrows) induced by IL-5-
activated eosinophils in the presence of BP autoantibodies (panel B) as well as a tight lining 
of eosinophils under these conditions along the dermal-epidermal junction after 3 h (panel 
C). Little DES is observed with normal serum only (panel D). Magnification x20. 
 
Figure 3 DES induced by eosinophils in the presence of IL-5 and BP autoantibodies 
requires FcγR activation and adhesion. (A) Histology. Quantification of DES induced by 
activated eosinophils in the presence and absence of F(ab’)2 antibody fragments against 
CD16, CD32 and CD64. Values are means of the % separation ± SEM. n=3. (B, C) 
Representative images (H&E) show the extent of DES (arrows) induced by activated 
eosinophils in the presence of control F(ab’)2 antibody fragments (panel B) and blocking 
F(ab’)2 antibody fragments against CD16, CD32 and CD64 (panel C). Magnification x20. (D) 
Histology. Quantification of DES induced by activated eosinophils in the presence and 
absence of F(ab’)2 antibody fragments against CD18. Values are means of the % separation 
± SEM. n=3. (E, F) Representative images (H&E) show the extent of DES (arrows) induced 
by activated eosinophils in the presence of control F(ab’)2 antibody fragments (panel E) and 
blocking F(ab’)2 antibody fragments against CD18 (panel F). Magnification x20. 
 
Figure 4 ROS production, degranulation and EET formation are involved in eosinophil-
mediated DES in the presence of IL-5 and BP autoantibodies. (A) Histology. Quantification 
of DES induced by activated eosinophils in the presence and absence of different 
concentrations of DPI. Values are means of the % separation ± SEM. *, p<0.05; **, p<0.01; 
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n=3. (B) Histology. Quantification of DES induced by activated eosinophils in the presence 
and absence of brefeldin A. Values are means of the % separation ± SEM. n=3. (C) 
Histology. Quantification of DES induced by activated eosinophils in the presence and 
absence of DNase. Values are means of the % separation ± SEM. n=3. (D-G) 
Representative images (H&E) show the extent of DES (arrows) induced by activated 
eosinophils in the absence of drugs (panel D) and in the presence of DPI (panel E), brefeldin 
A (panel F), and DNase (panel G). Magnification x20. (H) ROS production assay. ROS 
production by eosinophils was analyzed over a time period of 2 h. Eosinophils were 
activated as indicated. Conditions in the presence of BP antibodies are labelled in red. Data 
are representative of three independent experiments. 
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